Clover Health's Q3 Shows Strong Growth but Lacks Key Medical-Cost Detail

What happened

Clover Health's third quarter 2026 results delivered rapid growth, with Medicare Advantage membership up 45% year over year to 158,907 and total revenue up 53% to $759 million. GAAP net income of $6 million marked a $31 million improvement over the prior-year period, but was well below the $28 million reported in Q2 2026, suggesting profitability did not accelerate with revenue. Management raised full-year 2026 guidance across all key metrics, including revenue to $2.97-$3.00 billion, gross profit to $540-$555 million, GAAP net income to $25-$35 million, and adjusted EBITDA to $75-$85 million, implying a strong Q4. The company also highlighted a 5 Star rating for its flagship PPO for Payment Year 2028 and positive 2027 AEP momentum, supporting future growth. However, the press release omitted the insurance benefit expense ratio (BER) and per-member medical claims trends, which were identified as the most critical checkpoints in the prior analysis.

Implication

The raised guidance and strong membership growth support the bull case, but the sequential dip in net income from Q2 raises questions about margin durability. Investors should wait for the 10-Q to see BER and PMPM claims; if BER held near 87.6% and claims growth stayed below 5%, the thesis improves and the stock could re-rate toward the base-case value of $4.90. If BER deteriorated above 88% or claims growth accelerated, the bear case becomes more likely, with downside toward $3.20. The 5 Star rating for PY2028 is a positive signal but does not resolve the CMS appeal on the 2027 4.5-Star recalculation, which remains a key uncertainty. Until these data points are confirmed, the WAIT rating remains appropriate, with an attractive entry near $3.80 and trim above $5.60.

Thesis delta

The Q3 release modestly strengthens the growth leg of the thesis, as membership and revenue beat expectations and guidance was raised. However, the absence of BER and PMPM claims data means the primary risk to the thesis—medical cost control—remains unproven. The 5 Star rating for PY2028 is a positive signal but does not resolve the 2027 CMS appeal, so the overall call stays WAIT until the 10-Q verifies that claims trends are stable.